Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -1.51 Decreased by -77.09% | - |
| Aug 10, 23 | -3.24 Decreased by -575.00% | -4.50 Increased by +28.00% |
| May 10, 23 | -0.38 Increased by +26.92% | -0.09 Decreased by -322.22% |
| Mar 23, 23 | -0.56 Decreased by -40.00% | -0.34 Decreased by -64.71% |
| Nov 10, 22 | -0.85 Decreased by -304.76% | -0.40 Decreased by -112.50% |
| Aug 11, 22 | -0.48 Decreased by -50.00% | -0.41 Decreased by -17.07% |
| May 16, 22 | -0.52 Increased by +48.00% | - |
| Mar 31, 22 | -0.40 Decreased by -42.86% | -0.32 Decreased by -25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -2.42 M Increased by +93.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -6.95 M Increased by +69.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 107.00 K Decreased by -69.77% | -63.94 M Decreased by -160.40% | Decreased by -59.76 K% Decreased by -761.52% |
| Dec 31, 22 | 8.00 K Decreased by -99.01% | -26.32 M Decreased by -38.14% | Decreased by -329.02 K% Decreased by -13.82 K% |
| Sep 30, 22 | 138.00 K Decreased by -98.78% | -40.11 M Decreased by -302.91% | Decreased by -29.07 K% Decreased by -33.02 K% |
| Jun 30, 22 | 361.00 K Decreased by -87.24% | -22.77 M Decreased by -50.12% | Decreased by -6.31 K% Decreased by -1.08 K% |
| Mar 31, 22 | 354.00 K Decreased by -90.04% | -24.55 M Decreased by -75.62% | Decreased by -6.94 K% Decreased by -1.66 K% |
| Dec 31, 21 | 806.00 K Decreased by -55.40% | -19.05 M Decreased by -45.56% | Decreased by -2.36 K% Decreased by -226.33% |